Can AI replace 50% of all drug discovery research by autonomously designing and testing new molecules in silico using generative ai and quantum computing simulations ?

Pharmaceutical R&D is notoriously slow and expensive, but AI is already accelerating drug discovery. If an AI could not only generate molecules but also simulate their interactions with human biology at an unprecedented scale, it could render traditional lab-based research obsolete. The question isn’t whether AI can design drugs—it’s whether it can do it better than humans without needing human scientists to interpret the results.

---

Generative AI can today propose novel small-molecule structures with high predicted binding affinity to protein targets, and in-silico high-throughput screening on classical hardware already covers millions of candidates. However, fully autonomous, end-to-end discovery that combines generative design, quantum-grade docking, and lab validation remains out of reach: docking accuracy is still below the ~1 kcal/mol uncertainty needed for reliable affinity ranking, quantum simulations for large proteins are error-prone on near-term devices, and wet-lab synthesis/validation bottlenecks persist. Current demonstrations achieve partial automation (design → in-silico triage → partial synthesis), but no group has reached the 50 % throughput reduction threshold across a broad set of targets. SOURCE: McKinsey & Company — https://www.mckinsey.com/capabilities/quantumblack/our-insights/quantum-computing-in-drug-discovery

— Enriched May 10, 2026